Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2022


	June 30,		December 31,
	2022		2021
Accrued compensation	$	346,496	$	532,678
Accrued interest on preferred members’ interests		188,085		188,085
Accrued clinical research costs		667,321		138,522
Accrued director fees		—		31,000
Accrued professional fees		17,800		24,100
Other miscellaneous accrued expenses		12,491		7,375
	$	1,232,193	$	921,760